History | Adalimumab for the treatment of adults with psoriasis | Guidance | NICE

History

A list of downloadable documents created during development.

Other information

TA146 Adalimumab ar gyfer soriasis: deall canllawiau NICE (fformat MS Word) ^{MSWord 314 KB} 23 March 2009

Background information

Review decision - September 2010 information
Appendix A: Decision paper presented to the Institute's Guidance Executive ^{PDF 105 KB} 30 September 2010
Review proposal - August 2010 information
Appendix A: provisional matrix of stakeholders ^{PDF 29 KB} 23 August 2010
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 285 KB} 23 August 2010
NICE issues guidance on the use of adalimumab for the treatment of psoriasis in adults ^{PDF 29 KB} 06 December 2013
Review decision - July 2009 information
Review proposal - October 2008 information
Provisional matrix of consultees and commentators ^{MSWord 67 KB} 06 December 2013
Review decision - December 2008 information
Review decision - December 2008: table of comments ^{PDF 43 KB} 31 December 2008

Psoriasis - adalimumab: final appraisal determination (FAD)

Psoriasis - adalimumab: final appraisal determination (FAD) information
Psoriasis - adalimumab: final appraisal determination (FAD) ^{PDF 112 KB} 25 April 2008
Response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 62 KB} 25 April 2008
Consultee and commentator comments on the ACD
Wyeth Pharmaceuticals ^{PDF 153 KB} 25 April 2008
Welsh Assembly Government ^{PDF 13 KB} 25 April 2008
Royal College of Nursing ^{PDF 20 KB} 25 April 2008
Merck Serono ^{PDF 283 KB} 25 April 2008
Department of Health ^{PDF 13 KB} 25 April 2008
British Association of Dermatologists ^{PDF 13 KB} 25 April 2008
Abbott Laboratories ^{PDF 25 KB} 25 April 2008

Psoriasis - adlimumab: appraisal consultation

Psoriasis - adlimumab: appraisal consultation information
Psoriasis - adalimumab: appraisal consultation document information
Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing ^{PDF 179 KB} 01 February 2008
Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report ^{PDF 448 KB} 01 February 2008
Psoriasis - adalimumab: appraisal consultation - Non-manufacturer submissions
British Association of Dermatologists ^{PDF 107 KB} 01 February 2008
Psoriasis and Psoriatic Arthritis Alliance ^{PDF 48 KB} 01 February 2008
Psoriasis Association ^{PDF 49 KB} 01 February 2008
Royal College of Nursing ^{PDF 15 KB} 01 February 2008
Royal College of Physicians ^{PDF 43 KB} 01 February 2008
Welsh Assembly Government ^{PDF 50 KB} 01 February 2008
Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd ^{PDF 1.24 MB} 01 February 2008
Psoriasis - adalimumab: appraisal consultation - Expert written personal statements
Barker ^{PDF 17 KB} 01 February 2008
Chandler ^{PDF 22 KB} 01 February 2008
Griffiths ^{PDF 18 KB} 01 February 2008
Jobling ^{PDF 16 KB} 01 February 2008

Psoriasis - adalimumab: Draft scope - pre-referral

Psoriasis - adalimumab: Draft scope - pre-referral ^{PDF 32 KB} 07 September 2007

Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral

Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral ^{PDF 39 KB} 07 September 2007

Psoriasis - adalimumab: Response to comments on the draft scope

Psoriasis - adalimumab: Response to comments on the draft scope ^{PDF 126 KB} 06 August 2007